Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CardioComm Solutions Inc V.EKG

Alternate Symbol(s):  EKGGF

Healthcare Medical Devices
CardioComm Solutions, Inc. develops advanced software, hardware and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The Company’s proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research and telemedicine solutions for recording, transmission, viewing, analyzing, reporting and storage of ECGs. The Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud-based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. It also holds Class II medical device clearances for the manufacture, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.


TSXV:EKG - Post by User

CardioComm Solutions Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • mba123ccuX
Comment by mba123ccuon Jun 01, 2022 1:49pm
322 Views
Post# 34723946

RE:NR and Q1 results are out on Sedar

RE:NR and Q1 results are out on Sedar "The net profit and comprehensive profit for the period ended 31 March, 2022, was
$62,372 compared to a net loss and comprehensive loss for the period ended 31 March, 2021, of $57,792."

Small improvement over the corresponding period.
Happily chugging along.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities